Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
In millions, except per share items | Jun-30-23 | Mar-31-23 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 | Jun-30-21 |
| 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q |
Other | | | | | | | 1,425.4 | 1,167.7 |
Total revenues | | | | | | | 1,524.2 | 1,221.1 |
Revenue growth | | | | | | | 74.2% | 39.3% |
Cost of goods sold | | | | | | | 1,148.3 | 879.4 |
Gross profit | | | | | | | 375.9 | 341.7 |
Gross margin | | | | | | | 24.7% | 28.0% |
Selling, general and administrative [+] | | | | | | | 298.6 | 228.6 |
Sales and marketing | | | | | | | 123.6 | 86.9 |
General and administrative | | | | | | | 175.0 | 141.7 |
Research and development | | | | | | | 136.4 | 115.2 |
EBITDA [+] | | | | | | | -22.6 | 23.7 |
EBITDA growth | | | | | | | 24.1% | -148.5% |
EBITDA margin | | | | | | | -1.5% | 1.9% |
Depreciation | | | | | | | 17.9 | 16.4 |
EBITA | | | | | | | -40.5 | 7.3 |
EBITA margin | | | | | | | -2.7% | 0.6% |
Amortization of intangibles | | | | | | | 18.3 | 9.3 |
EBIT [+] | | | | | | | -58.9 | -2.0 |
EBIT growth | | | | | | | 86.0% | -96.8% |
EBIT margin | | | | | | | -3.9% | -0.2% |
Interest expense, net [+] | | | | | | | 19.0 | 17.7 |
Interest expense | | | | | | | 19.7 | 18.5 |
Interest income | | | | | | | 0.7 | 0.8 |
Other income (expense), net [+] | | | | | | | 14.9 | 9.5 |
Other | | | | | | | 4.1 | -0.6 |
Pre-tax income | | | | | | | -63.2 | -10.4 |
Income taxes | | | | | | | 5.4 | 5.1 |
Net income | | | | | | | -76.1 | -23.5 |
Net margin | | | | | | | -5.0% | -1.9% |
|
Basic EPS [+] | | | | | | | ($0.74) | ($0.23) |
Growth | | | | | | | 61.9% | -68.5% |
Diluted EPS [+] | | | | | | | ($0.74) | ($0.23) |
Growth | | | | | | | 65.2% | -68.7% |
|
|
Shares outstanding (basic) [+] | | | | | | | 102.9 | 101.6 |
Growth | | | | | | | 7.3% | 8.1% |
Shares outstanding (diluted) [+] | | | | | | | 102.9 | 103.5 |
Growth | | | | | | | 5.1% | 8.7% |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|